vs
博士伦健康（BHC）与罗克韦尔自动化（ROK）财务数据对比。点击上方公司名可切换其他公司
博士伦健康的季度营收约是罗克韦尔自动化的1.3倍（$2.8B vs $2.1B），罗克韦尔自动化净利率更高（14.5% vs -3.7%，领先18.2%），罗克韦尔自动化同比增速更快（11.9% vs 9.3%），博士伦健康自由现金流更多（$403.0M vs $170.0M），过去两年博士伦健康的营收复合增速更高（14.0% vs -0.5%）
博士伦健康公司（Bausch Health）是一家业务多元化的北美跨国制药企业，全球总部位于加拿大魁北克省拉瓦尔，美国总部设在新泽西州布里奇沃特。公司专注于胃肠病、肝病、神经科、皮肤科、牙科、医疗美容等领域的药物研发、生产及销售，同时提供品牌药和仿制药产品，业务覆盖全球市场。
罗克韦尔自动化是总部位于美国威斯康星州密尔沃基的工业自动化及数字化转型技术提供商，旗下拥有Allen-Bradley、FactoryTalk软件、LifecycleIQ服务等核心品牌，全球员工约2.7万人，服务覆盖100多个国家和地区的客户。
BHC vs ROK — 直观对比
营收规模更大
BHC
是对方的1.3倍
$2.1B
营收增速更快
ROK
高出2.6%
9.3%
净利率更高
ROK
高出18.2%
-3.7%
自由现金流更多
BHC
多$233.0M
$170.0M
两年增速更快
BHC
近两年复合增速
-0.5%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $2.8B | $2.1B |
| 净利润 | $-103.0M | $305.0M |
| 毛利率 | — | 48.3% |
| 营业利润率 | 17.0% | 20.7% |
| 净利率 | -3.7% | 14.5% |
| 营收同比 | 9.3% | 11.9% |
| 净利润同比 | -205.1% | 65.8% |
| 每股收益（稀释后） | $-0.30 | $2.69 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BHCROK
| Q4 25 | $2.8B | $2.1B | ||
| Q3 25 | $2.7B | $2.3B | ||
| Q2 25 | $2.5B | $2.1B | ||
| Q1 25 | $2.3B | $2.0B | ||
| Q4 24 | $2.6B | $1.9B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.4B | $2.1B | ||
| Q1 24 | $2.2B | $2.1B |
净利润BHCROK
| Q4 25 | $-103.0M | $305.0M | ||
| Q3 25 | $179.0M | $138.0M | ||
| Q2 25 | $148.0M | $295.0M | ||
| Q1 25 | $-58.0M | $252.0M | ||
| Q4 24 | $98.0M | $184.0M | ||
| Q3 24 | $-85.0M | $239.1M | ||
| Q2 24 | $10.0M | $232.0M | ||
| Q1 24 | $-64.0M | $266.2M |
毛利率BHCROK
| Q4 25 | — | 48.3% | ||
| Q3 25 | — | 69.4% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 40.5% | ||
| Q4 24 | — | 38.4% | ||
| Q3 24 | — | 37.9% | ||
| Q2 24 | — | 38.8% | ||
| Q1 24 | — | 39.2% |
营业利润率BHCROK
| Q4 25 | 17.0% | 20.7% | ||
| Q3 25 | 23.1% | 2.7% | ||
| Q2 25 | 17.5% | 16.0% | ||
| Q1 25 | 12.2% | 14.9% | ||
| Q4 24 | 21.8% | 17.1% | ||
| Q3 24 | 12.7% | 13.5% | ||
| Q2 24 | 16.2% | 12.4% | ||
| Q1 24 | 13.1% | 14.6% |
净利率BHCROK
| Q4 25 | -3.7% | 14.5% | ||
| Q3 25 | 6.7% | 6.0% | ||
| Q2 25 | 5.8% | 13.8% | ||
| Q1 25 | -2.6% | 12.6% | ||
| Q4 24 | 3.8% | 9.8% | ||
| Q3 24 | -3.4% | 11.7% | ||
| Q2 24 | 0.4% | 11.3% | ||
| Q1 24 | -3.0% | 12.5% |
每股收益（稀释后）BHCROK
| Q4 25 | $-0.30 | $2.69 | ||
| Q3 25 | $0.48 | $1.24 | ||
| Q2 25 | $0.40 | $2.60 | ||
| Q1 25 | $-0.16 | $2.22 | ||
| Q4 24 | $0.24 | $1.61 | ||
| Q3 24 | $-0.23 | $2.09 | ||
| Q2 24 | $0.03 | $2.02 | ||
| Q1 24 | $-0.17 | $2.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.3B | $444.0M |
| 总债务越低越好 | $20.8B | — |
| 股东权益账面价值 | $-554.0M | $3.7B |
| 总资产 | $26.4B | $11.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BHCROK
| Q4 25 | $1.3B | $444.0M | ||
| Q3 25 | $1.3B | $468.0M | ||
| Q2 25 | $1.7B | $495.0M | ||
| Q1 25 | $1.1B | $456.0M | ||
| Q4 24 | $1.2B | $477.0M | ||
| Q3 24 | $719.0M | $471.3M | ||
| Q2 24 | $595.0M | $407.0M | ||
| Q1 24 | $733.0M | $470.5M |
总债务BHCROK
| Q4 25 | $20.8B | — | ||
| Q3 25 | $21.0B | $2.6B | ||
| Q2 25 | $21.7B | — | ||
| Q1 25 | $21.5B | — | ||
| Q4 24 | $21.6B | — | ||
| Q3 24 | $21.5B | $2.6B | ||
| Q2 24 | $21.7B | — | ||
| Q1 24 | $22.1B | — |
股东权益BHCROK
| Q4 25 | $-554.0M | $3.7B | ||
| Q3 25 | $-565.0M | $3.7B | ||
| Q2 25 | $-764.0M | $3.5B | ||
| Q1 25 | $-1.2B | $3.4B | ||
| Q4 24 | $-1.3B | $3.4B | ||
| Q3 24 | $-1.2B | $3.5B | ||
| Q2 24 | $-1.2B | $3.3B | ||
| Q1 24 | $-1.1B | $3.5B |
总资产BHCROK
| Q4 25 | $26.4B | $11.2B | ||
| Q3 25 | $26.8B | $11.2B | ||
| Q2 25 | $27.3B | $11.2B | ||
| Q1 25 | $26.4B | $11.0B | ||
| Q4 24 | $26.5B | $10.9B | ||
| Q3 24 | $26.5B | $11.2B | ||
| Q2 24 | $26.5B | $11.2B | ||
| Q1 24 | $26.9B | $11.4B |
负债/权益比BHCROK
| Q4 25 | — | — | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.73× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $495.0M | $234.0M |
| 自由现金流经营现金流 - 资本支出 | $403.0M | $170.0M |
| 自由现金流率自由现金流/营收 | 14.4% | 8.1% |
| 资本支出强度资本支出/营收 | 3.3% | 3.0% |
| 现金转化率经营现金流/净利润 | — | 0.77× |
| 过去12个月自由现金流最近4个季度 | $1.0B | — |
8季度趋势，按日历期对齐
经营现金流BHCROK
| Q4 25 | $495.0M | $234.0M | ||
| Q3 25 | $405.0M | $454.0M | ||
| Q2 25 | $289.0M | $527.0M | ||
| Q1 25 | $211.0M | $199.0M | ||
| Q4 24 | $601.0M | $364.0M | ||
| Q3 24 | $405.0M | $432.3M | ||
| Q2 24 | $380.0M | $279.1M | ||
| Q1 24 | $211.0M | $119.8M |
自由现金流BHCROK
| Q4 25 | $403.0M | $170.0M | ||
| Q3 25 | $314.0M | — | ||
| Q2 25 | $190.0M | $489.0M | ||
| Q1 25 | $96.0M | $171.0M | ||
| Q4 24 | $495.0M | $293.0M | ||
| Q3 24 | $334.0M | — | ||
| Q2 24 | $302.0M | $238.4M | ||
| Q1 24 | $129.0M | $68.6M |
自由现金流率BHCROK
| Q4 25 | 14.4% | 8.1% | ||
| Q3 25 | 11.7% | — | ||
| Q2 25 | 7.5% | 22.8% | ||
| Q1 25 | 4.2% | 8.5% | ||
| Q4 24 | 19.3% | 15.6% | ||
| Q3 24 | 13.3% | — | ||
| Q2 24 | 12.6% | 11.6% | ||
| Q1 24 | 6.0% | 3.2% |
资本支出强度BHCROK
| Q4 25 | 3.3% | 3.0% | ||
| Q3 25 | 3.4% | — | ||
| Q2 25 | 3.9% | 1.8% | ||
| Q1 25 | 5.1% | 1.4% | ||
| Q4 24 | 4.1% | 3.8% | ||
| Q3 24 | 2.8% | — | ||
| Q2 24 | 3.2% | 2.0% | ||
| Q1 24 | 3.8% | 2.4% |
现金转化率BHCROK
| Q4 25 | — | 0.77× | ||
| Q3 25 | 2.26× | 3.29× | ||
| Q2 25 | 1.95× | 1.79× | ||
| Q1 25 | — | 0.79× | ||
| Q4 24 | 6.13× | 1.98× | ||
| Q3 24 | — | 1.81× | ||
| Q2 24 | 38.00× | 1.20× | ||
| Q1 24 | — | 0.45× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BHC
| Bausch Lomb | $1.4B | 50% |
| Salix Segment | $693.0M | 25% |
| International Rx | $306.0M | 11% |
| Diversified Segment | $255.0M | 9% |
| Solta Medical Segment | $137.0M | 5% |
ROK
| Productsand Solutions | $1.9B | 89% |
| Lifecycle Services Segment | $259.0M | 12% |
